Secondary analysis of EMERALD in HER2+ advanced breast cancer: with trastuzumab + pertuzumab, eribulin gave similar PFS to docetaxel (14.0 vs 13.1 months; HR 0.94) and paclitaxel (14.1 vs 10.8; HR 1.00). More neutropenia with eribulin; QoL held longer.
Secondary analysisn = 446
Masuda et al. Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD